用于心脏修复的细胞及细胞贴片（英文版）

cellandcellpatchesforcardiacrepair革新心脏修复的细胞疗法目录第一章第二章第三章BackgroundandChallengesofCardiacRepairOverviewofCellTherapyandBiomaterialsDesignofNewMicroNeedleSMTTechnology目录第四章第五章第六章RepairmechanismandmicroenvironmentregulationAnimalmodelexperimentresultsClinicaltranslationandfuturedirectionsBackgroundandChallengesofCardiacRepair1.Coronaryatheroscleroticplaquerupture:Themostcommonpathologicalbasisofmyocardialinfarctionistheruptureofvulnerableplaqueinthecoronaryartery.Theexposedlipidcoreactivatesplateletaggregationandthrombosis,leadingtoacuteocclusionofbloodvesselsandinterruptionofmyocardialbloodflow.Plaqueruptureiscloselyrelatedtofactorssuchasinflammatoryresponseandbloodflowshearforce.Cascadereactionofmyocardialischemiaandnecrosis:Aftercoronaryarteryocclusion,myocardialcellsexperienceenergymetabolismdisorders,intracellularacidosis,andcalciumoverloadduetohypoxia,ultimatelyleadingtocellapoptosisornecrosis.Theischemiccoreareaofthemyocardiumundergoesirreversibledamagewithin30minutesandgraduallyexpandstotheperiphery.Ventricularremodelingandfibrosis:Necroticmyocardiumisreplacedbyfibrousscars,leadingtopathologicalremodelingoftheheartstructure,includingexpansionoftheinfarctedareaandhypertrophyofthenoninfarctedarea,ultimatelyresultinginprogressivedeclineinheartfunctionandbecomingthemainmechanismofchronicheartfailure.PathologicalbasisofmyocardialinfarctionAdultmyocardialcellshaveextremelylowproliferationability:Afterbirth,mammalianmyocardialcellsexitthecellcycle,withlimitedregenerationability,unabletoeffectivelyreplenishthemyocardialcelllossintheinfarctedarea,andscartissuelackscontractilefunction.Thedirectionofstemcelldifferentiationisuncontrollable:althoughmyocardialstemcellshavedifferentiationpotential,theymaydifferentiateintofibroblastsinsteadoffunctionalmyocardialcellsaftertransplantation,andeveninducearrhythmia,withlowsurvivalrateandpoorintegrationefficiency.Inflammatorymicroenvironmenthindersrepair:Theinflammatoryresponseafterinfarctionreleasesalargeamountofcytokinesandreactiveoxygenspecies,inhibitsendogenousstemcellactivation,andacceleratestheapoptosisofremainingmyocardialcells,formingaviciouscycle.Insufficientvascularregeneration:Newlyformedmyocardialtissuerequiresamatchingvascularnetworksupport,butexistingtechnologyisdifficulttoachievesynchronousvascularregeneration,resultingintransplantedcellsdyingagainduetoischemia.LimitationsofcardiactissueregenerationShortcomingsandNeedsofExistingTherapiesLimitationsofstent/bypassgrafting:Bloodflowreconstructiononlyrestoresbloodflowandcannotreversenecroticmyocardium.Postoperativerestenosisandnoreflowphenomenonarecommon,anditisineffectiveformicrocirculationdisorders.Thepassivityofdrugtherapy:Anticoagulants,betablockers,andotherdrugsonlydelaydiseaseprogressionandcannotpromotemyocardialregeneration,withlimitedeffectivenessforend-stageheartfailure.Thesupply-demandcontradictionofhearttransplantation:donorshortage,immunerejection,andhighcostlimititswidespreadapplication,andthereisanurgentneedtodevelopalternativeregenerativetherapiestorepairdamagedmyocardium.OverviewofCellTherapyandBiomaterials2.Lowdeliveryefficiency:PreclinicalandclinicaltrialdataindicatethatintravenousinjectionofCAR-Tcellshasextremelylowhomingefficiencyinsolidtumors,withmostcellsremaininginthelungsandsecondarylymphoidorgans,andonlyasmallamountabletopenetratethetumormatrixbarrier.Themainreasonsarechemokinereceptormismatch,adhesionmoleculedefects,andextracellularmatrixobstruction.Insufficienttargeting:TheheterogeneityofsolidtumorantigensandinsufficienttargetspecificityleadtodifficultiesinCAR-Tcellrecognition.TheCD19targetingstrategyhasbeensuccessfulinhematologicalmalignancies,butsolidtumorslacksimilarhighlyspecifictargetsandrequirethedevelopmentofmulti-targetortumormicroenvironmentresponsiveCARdesigns.Persistentdefects:Tcellsinthesamegenemousemodelonlysurviveforafewweeks,andrapiddepletionofeffectorcellshasalsobeenobservedinhumanexperiments.ShortactingCAR-Tcombinedwithhigh-doseinfusionorstemcell-derivedTcellsmaybeasolution.ClinicallessonsofcelltherapyChemokinemediatedmigration:ExtracellularvesiclescarrychemokinessuchasCXCL9/10/11andCCL5,guidingTcellstocrossthevascularendothelium.Mesenchymalstemcellsintumorstromaestablishachemicalgradientthroughextracellularvesicles,butabnormalsecretioncancauseTcellsto"misnavigate"tolymphoidtissue.Regulationofadhesionmolecules:IntegrinsandselectinsonthesurfaceofextracellularvesiclesparticipateinthecascadereactionofTcellrollingadhesionandfirmadhesion.TheabsenceofICAM1blocksthefinaltumorinfiltrationandrequiresengineeringmodificationofextracellularvesiclestoenhanceadhesionability.Immuneeditingfunction:TumorderivedexosomescandeliverPD-L1orTGF-βandinhibitCAR-Tactivity.Reverseutilizationofengineeredexosomestodeliverimmunestimulatoryfactors(suchasIL-12)canreshapethemicroenvironment.Barrierpenetrationcharacteristics:Thesizeofextracellularvesicles(30-150nm)endowsthemwiththeabilitytopenetratedenseextracellularmatrixandcanserveasdrugcarrierstoassistCAR-Tinbreakingthroughphysicalbarriers,butheterogeneityissuesneedtobeaddressedinlarge-scaleproduction.ThemechanismofactionofextracellularvesiclesPositioningenhancementsystem:thehydrogelsustained-releaseplatformcandeliverCAR-Tcellslocally,avoidingthewholebodydistribution.Temperature/pHresponsivematerialscanachievetumorspecificreleaseandincreasetargetcellconcentrationby5-10times.Artificialantigenpresentationscaffold:abiomimeticmaterialthatsimulateslymphnodestructureandmaintainsTcellactivationthroughCD3/CD28antibodymodification.DegradablestentscanextendthesurvivaltimeofCAR-Tintumorstomorethan4weeks.Physicalbarrierbreaking:Matrixmetalloproteinase(MMP)responsivenanoparticlescandegradecollagenbarriers,andcombinedwithhyaluronidasematerials,cansignificantlyincreaseTcellpenetrationdepth,leadingtoa3-foldincreaseintumorcoreinfiltrationrate.TheroleofbiomaterialsindeliveryDesignofNewMicroNeedleSMTTechnology3.IL-4encapsulationandPLGAparticlestructurePrecisecontrolledreleasedesign:PLGAmicrospheresachievesustainedreleaseofIL-4byadjustingtheLA/GAratio(e.g.75:25),withadegradationcyclethatcancoverseveralweekstomonths.TheirhydrophobicityprotectsIL-4fromenzymatichydrolysis,whileendgroupmodificationoptimizesdrugloading.Multilayerstructureoptimization:coreshellstructureispreparedbylotionmethod,theinnerlayerisIL-4-PLGAcomplex(molecularweight10-50kDa),andtheouterlayeriscoatedwithresponsivematerials(suchaspHsensitivepolymers)toensuretargetedreleaseofinflammatorysites.Collaborativefunctionalintegration:PLGAmicrospherescombinedwithnanoarmortechnologyenhancestabilitythroughbiomimeticmulti-layerdesign(suchaspolyethyleneglycolouterlayer),andintegratereactiveoxygenspeciesscavengingabilitytoimproveanti-inflammatoryeffects.Efficienttransdermaldelivery:HyaluronicacidmicroneedlesutilizetheirnaturalviscoelasticitytopenetratethestratumcorneumanddirectlydeliverIL-4tothedermislayer,avoidingfirstpasseffectsandincreasingbioavailabilitybyover80%comparedtooralformulations.Microenvironmentresponsiveness:Hyaluronicacidcanbedegradedbyhighlyexpressedhyaluronidaseatthesiteofinflammation,enablingon-demandreleaseofIL-4.Atthesametime,itsinherentanti-inflammatorypropertiescansynergisticallyinhibitM1macrophageactivation.Adjustablemechanicalproperties:Byregulatingthehardnessofmicroneedlesthroughcrosslinkingdegree(elasticmodulus0.1-1GPa),itensurespunctureefficiencyandavoidsbreakage,andissuitablefordifferentskinthicknesses(suchasinfantsandadults).Promotingtissuerepair:HyaluronicacidactivatestheCD44receptorpathway,stimulatesfibroblastmigrationandcollagendeposition,accelerateswoundhealing,andisparticularlysuitableforskinlesionsrelatedtochronicinflammatoryboweldisease.AdvantagesofhyaluronicacidmicroneedlepatchNontoxicmetabolites:PLGAisdegradedintolacticacidandglycolicacid,completelymetabolizedintoCO2andwaterthroughthetricarboxylicacidcycle,withnoresidualtoxicity,andmeetsFDA/EMAmedicalmaterialstandards(suchasLupronDepot)®Applicationcase).Controllabledegradationrate:ByadjustingtheLA/GAratio(50:50to85:15)andmolecularweight(5-100kDa)ofPLGAtomatchdifferenttreatmentcyclerequirements(suchasshort-termimmuneregulationorlong-termbonerepair).Immunoinertness:ClinicalgradePLGA(terminalcarboxylation)andhyaluronicacidmicroneedlesbothshowedextremelylowimmunogenicity,andmacrophagepolarizationexperimentsconfirmedthatM2typeaccountedforover70%,significantlybetterthantraditionalpolymercarriers.BiocompatibilityanddegradationcharacteristicsRepairmechanismandmicroenvironmentregulation4.MacrophagepolarizationinductionM2macrophageactivation:iECMpromotespolarizationofreparativeM2macrophagesbyupregulatingmarkerssuchasArg1andCD206,whileinhibitingM1inflammationrelatedgenes(suchasIL-1βandTNF-α),resultinginreducedheterogeneityofimmunecellinfiltrationintheinfarctedareainthespatialtranscriptome.Regulationofmonocyterecruitment:iECMsignificantlyreducestheinfiltrationofpro-inflammatorymonocytes(CXCR2+,CCL2+)duringtheacutephase(within1day),andinhibitscellmigrationthroughintegrinreceptorCD44,therebyoptimizingtheinflammatorymicroenvironment.Metabolicreprogrammingeffect:Acidic(pH6.5-7.0)andhypoxic(HIF-1αstable)microenvironmentsactivatetheGPR4/ASIC3pathwayandupregulateVEGF/Arg-1,synergisticallypromotingmacrophagepolarizationtowardsM2type.PromotionofmyocardialcellproliferationActivationofmononucleardiploidcardiomyocytes:Researchhasfoundthatthereisasubpopulationofmononucleardiploidcardiomyocyteswithproliferativeabilityintheheart.Inhibitingtheirpolyploidizationcanenhancetheregenerativeabilityoftheadultheartandreducefibrosisscarformation.Epigeneticregulation:RBM22,asacorecomponentofspliceosomes,canovercometranscriptionalandepigeneticbarrierstomyocardialcellproliferationbyrestoringitsexpression,providinganewtargetforendogenousregeneration.Applicationofconductivebiomaterials:TheGeGenconductiveheartpatchisdesignedwithabiomimetictreefrogfootstructuretoimprovetheretentionrateofnanoparticlesinthedynamicheartmicroenvironment,directlypromotingtheelectricalsignaltransmissionandproliferationofmyocardialcells.Dendriticcellfunctioninhibition:iECMdownregulatesMHC-IImolecules(CD74)andantigenpresentationrelatedgenes(AHR,MTCP1),blocksabnormalTcellactivation,andreducesinflammatorycascadereactions.Regulationoflymphangiogenesis:After7daysofiECMtreatment,themyocardiallymphaticvesseldensityincreasedby2.1times,promotingtheproliferationoflymphaticendothelialcells(Prox1+/FLT4+)throughtheSLIT1/VEGFApathwayandacceleratingtheclearanceofinflammatoryfactors.SpecificeffectsofECMcomponents:HeartderivedECMtendstoinduceM2polarization,whilebonederivedECMpromotesM1polarization,indicatingthatmatrixcomponentshavetissue-specificregulatoryabilityonmacrophagepolarization.MechanismofinflammationsignalinhibitionAnimalmodelexperimentresults5.Heartfunctionimprovement:Inthedualstemcelltherapyexperiment,theheartfunctionoftheratmodelwasimprovedbymorethan20%.BysimultaneouslydeliveringhiPSCCMsandhMSCs,thecontractileabilityoftheheartwassignificantlyimproved.Fibrosisreduction:Experimentalresultsshowedthatscartissueintheheartwasreducedbynearlyhalf,indicatingthatstemcelltherapyeffectivelyinhibitedthefibrosisprocessandpromotedtheregenerationofhealthytissue.Angiogenesis:hMSCspatchescontinuouslyreleasegrowthfactorssuchasVEGFandIGF-1,promotingvascularreconstructioninischemicareasandprovidingnecessarynutrientsandoxygenformyocardialrepair.Synergisticeffect:hiPSCCMsfillthegapinmyocardialcells,whilehMSCsprovideprotectionandsupport,andthesynergisticeffectofthetwoachievescomprehensivecardiacrepair.ImprovementofratmodelfunctionCellsurvivalrate:PigmodelexperimentsshowedthatSIS-ECMpatchesinoculatedwithhCVPCandhCMsignificantlyimprovedcellsurvivalrateandformedfunctionaltissueintheinfarctedarea.Structuralimprovement:PigheartsimplantedwithSISMixpatchesexhibitbetterventricularstructureandlessscarformation,demonstratingthesynergisticeffectofdualcellseeding.Parasecretioneffect:SISpatchstimulatestheproliferationofhostcardiomyocytesthroughparacrinemechanism,furtherenhancingtherepairabilityoftheheart.VerificationofOrganizationalIntegrityinPigModelsContractionfunctionrecovery:GPS@AuNPsheartpatchessignificantlyimproveventricularsystolicfunctionthroughconductivepathwaysandbiomimeticstructures,bringingitclosetonormallevels.Mechanicalmatching:Thefatigueresistanceofthepatchreachesthethresholdof50kPa,andthewetadhesionstrengthexceeds1kPa,achievinggoodspatiotemporalmatchingwiththedynamiccontractionofthemyocardium.Electricalsignaltransmission:Theconductivepathwayformedbygoldnanoparticlesensurestherapidtransmissionofelectricalsignalsandpromotessynchronouscontractionofmyocardialcells.BiologicalFunctionOptimization:The3Dprintedtreefrogfootpadstructurefurtheroptimizesthemechanicalpropertiesandbiologicalfunctionsofthepatch,achievingmultidimensionalsynergisticeffects.ImprovementofventricularsystolicfunctionClinicaltranslationandfuturedirections6.Pigmodelvalidation:Thecoronaryarterydiameterofpigs(3.0-4.0mm)ishighlycompatiblewithhumans,andthesimilarityinvascularwallstructureandcoagulationsystemmakesitthepreferredmodelfordrugballoonstentexperiments.Accuratepositioningcanbeachievedthroughopenchestsurgeryorpercutaneouscoronaryintervention(PCI),whichcansimulateclinicalscenariossuchasinstentrestenosis.PleaseconsultZhouGongat136-3232-1689fortechnicaladvice.Multidimensionalmonitoring:Theexperimentrequiressettingupexperimentalgroups(suchasrapamycincoateddrugloadingof3μg/mm²),blankballoongroups,andbaremetalstentgroups,withatleast6-8animalsineachgroup.Realtimeevaluationofstentadherence,vascularinjury,andstenosisdiameterpercentagethroughangiography,OCT,andIVUStoensurestatisticalvalidityofthedata.SafetyassessmentoflargeanimalsSevereheartfailuretreatment:Domesticmagneticlevitationventricularassistdevices(suchasHeartCon)havesurvivedfo